Loading company…
YiPSCELL uses induced pluripotent stem cell technology for disease modeling, research and therapeutic development.
YiPSCELL provides disease modeling, cell line and analysis services using induced multifunctional stem cell technology, and develops stem cell-based therapeutic agents. Established in 2017 and based in Seoul, South Korea, it raised KRW 12 billion in Series A funding in June 2021, led by InterVest, with participation from AJU IB Investment, HB Investment and Premier Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in